Journal of Cell Science, Vol 107, Issue 1 39-46, Copyright © 1994 by Company of Biologists

JOURNAL ARTICLES

Comparison of normal and tumorigenic endothelial cells: differences in thrombospondin production and responses to transforming growth factor-beta

A RayChaudhury, WA Frazier and PA D'Amore
Laboratory for Surgical Research, Children's Hospital, Boston, MA 02115.

Cultured endothelial cells constitutively synthesize significant levels of thrombospondin, an extracellular matrix-associated protein with reported anti-anti-angiogenic properties. However, two murine endothelial cell lines, bEND.3 and Py-4-1, which have been immortalized with polyoma T oncogenes and which generate vascular malformations in vivo, produce little or no thrombospondin though bEND.3 (but not Py-4-1) growth is inhibited by the addition of exogenous thrombospondin. In addition, Py-4-1 cells are not growth-inhibited by transforming growth factor-beta, a potent endothelial inhibitor. These results indicate that these two cell lines may be useful tools in understanding the role and mechanism of action of thrombospondin and transforming growth factor-beta in endothelial cell biology. A role for thrombospondin in vascular development is further suggested by the observation of significant differences in the levels of thrombospondin mRNA and protein between capillary and aortic endothelial cells. Transforming growth factor-beta-1 treatment of normal endothelial cells increases steady-state levels of thrombospondin mRNA and protein and results in extensive deposition of thrombospondin into the extracellular matrix. In contrast, transforming growth factor-beta-1 has little effect on thrombospondin levels in the tumorigenic endothelial cell lines. In view of our earlier finding that contact between endothelial cells and mural cells generates activated transforming growth factor-beta-1, and the fact that thrombospondin is present in a fibrillar network around vascular structures in vitro, we speculate that modulation of thrombospondin production and distribution by transforming growth factor-beta may be a physiological process to enjoin stabilization of vessels and cessation of vessel growth.

This article has been cited by other articles:

				M.-L. Chang, J.-C. Chen, C. R. Alonso, A. R. Kornblihtt, and D. M. Bissell Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver PNAS, December 28, 2004; 101(52): 18093 - 18098. [Abstract] [Full Text] [PDF]

				D. Chen, T. Asahara, K. Krasinski, B. Witzenbichler, J. Yang, M. Magner, M. Kearney, W. A. Frazier, J. M. Isner, and V. Andres Antibody Blockade of Thrombospondin Accelerates Reendothelialization and Reduces Neointima Formation in Balloon-Injured Rat Carotid Artery Circulation, August 24, 1999; 100(8): 849 - 854. [Abstract] [Full Text] [PDF]

				D. Gabrilovich, T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D. P. Carbone Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo Blood, December 1, 1998; 92(11): 4150 - 4166. [Abstract] [Full Text] [PDF]

				N. Sheibani and W. A. Frazier Down-Regulation of Platelet Endothelial Cell Adhesion Molecule-1 Results in Thrombospondin-1 Expression and Concerted Regulation of Endothelial Cell Phenotype Mol. Biol. Cell, April 1, 1998; 9(4): 701 - 713. [Abstract] [Full Text]

				D. W. Dawson, S. F. A. Pearce, R. Zhong, R. L. Silverstein, W. A. Frazier, and N. P. Bouck CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells J. Cell Biol., August 11, 1997; 138(3): 707 - 717. [Abstract] [Full Text] [PDF]